ORAL COMPOSITION X842 Russian patent published in 2025 - IPC A61K31/437 A61K45/08 A61K47/14 A61K47/20 A61K47/26 A61K47/38 A61P1/04 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutics, namely to oral composition X842 (5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid) for immediate release and use of such a composition in treating or preventing a gastrointestinal inflammatory disease or a disease associated with gastric acid, in which inhibition of gastric acid secretion is necessary or desirable. Immediate release oral composition X842 containing a therapeutically effective amount of X842 and sodium dodecyl sulphate in amount of 8.0 to 12.0  wt./wt.% relative to the number of X842. Use of said composition in treating or preventing a gastrointestinal inflammatory disease or a disease associated with gastric acid, in which inhibition of gastric acid secretion is necessary or desirable. Use of said composition in the treatment or prevention of a gastrointestinal inflammatory disease or a disease associated with gastric acid, in which inhibition of gastric acid secretion is necessary or desirable, selected from gastritis, gastroesophageal reflux disease (GERD), erosive gastroesophageal reflux disease (eGERD), H. pylori infection, Zollinger-Ellison syndrome, peptic ulcer disease, bleeding gastric ulcer, gastroesophageal reflux disease symptoms, gastrinoma and acute upper gastrointestinal haemorrhage.

EFFECT: said group of inventions makes it possible to create composition X842, which quickly dissolves in stomach after oral administration, suitable for eradication of Helicobacter pylori and treatment of diseases characterized by gastroesophageal reflux.

12 cl, 3 tbl, 3 ex